Part 1: Patient with any advanced or metastatic solid tumor
Part 2A: Patient with any advanced or metastatic solid tumor
Histologic or cytologic confirmation of a solid tumor that is advanced (metastatic, recurrent, and/or unresectable) with measurable disease and have at least 1 lesion accessible for biopsy
Histopathologically confirmed melanoma, Merkel cell carcinoma or other solid tumor malignancy
Group A: Subjects with any solid tumor (including lymphomas).
Histologic or cytologic confirmation of an incurable solid malignancy that is advanced (metastatic and/or unresectable), with measurable disease per RECIST v1.1
Histologic or cytologic confirmation of a solid tumor that is advanced (metastatic, recurrent, and/or unresectable) with measurable disease and have at least 1 lesion accessible for biopsy
histologic or cytologic confirmation of a solid tumor that is advanced (metastatic, recurrent and/or unresectable)
For Ph1a monotherapy and combination cohorts, histologic or cytologic confirmation of advanced solid tumor.
Diagnosis of advanced solid tumor cancer, lymphoma, or myeloma (no time restrictions or limitations) -OR- diagnosis of early stage solid tumor cancer, lymphoma, or myeloma <= 12 months prior to study enrollment
Patient with advanced or metastatic solid tumor and has disease progression or treatment intolerance after treatment with available therapies
Advanced melanoma or PD-L1-positive advanced, relapsed, or refractory solid tumor or lymphoma
Has a diagnosis of locally advanced or metastatic solid tumor
Solid tumor located in central lung
Malignancy (solid tumor or lymphoma) that is currently not amenable to surgical intervention due to either medical contraindications or nonresectability of the tumor.
If the study Sponsor decides to evaluate additional solid tumors, subjects must satisfy following criteria to be included in the study: Has a pathologically documented advanced solid tumor.
Histologic or cytologic confirmation of a solid tumor that is advanced (metastatic, recurrent and/or unresectable) with measurable disease per RECIST v1.1
Radiographically confirmed solid tumor brain metastases
Advanced solid tumor malignancy without curative options
Malignancy (solid tumor or lymphoma) that is currently not amenable to surgical intervention due to either medical contraindications or non-resectability of the tumor.
Histologic proof or unequivocal cytologic proof of solid tumor malignancy; this may be obtained from either the primary or any metastatic site
Pathologically-proven diagnosis of a solid tumor malignancy
Advanced, solid tumor malignancy that is amenable to biopsy; patient must consent to 4 mandatory biopsies during study
Pathological diagnosis of any solid tumor histology (from any site in the body)
Pathologic confirmation of solid tumor, including central nervous system tumor or lymphoma, or leukemia
Histologic, cytologic, or radiologically evidence of locally advanced, residual, or recurrent solid malignancy of the abdomen or pelvis requiring surgical resection
Histologic or cytologic confirmation of advanced solid tumor.
Pathologically confirmed advanced solid tumor cancers
Subject must have advanced solid tumor that is not amenable to surgical resection or other approved therapeutic options that have demonstrated clinical benefit but based on evidence gathered in this study or from external sources, the Sponsor in consultation with the Investigators, may decide to limit to specific tumor types.
Patients with a hematologic malignancy or solid tumor
Patients with more than one malignancy (hematologic or solid tumor) are eligible
Histologically documented diagnosis of solid tumor
Diagnosis of advanced solid tumor or hematologic malignancy (limited to lymphoma) that has failed or become intolerant to standard therapy
Malignancy (solid tumor or lymphoma) that is currently not amenable to surgical intervention due to either medical contraindications or nonresectability of the tumor.
advanced or metastatic solid tumor (Part A)
Subject must have an advanced solid tumor
cMET dysregulated advanced solid tumor
Any advanced unresectable/stage IV solid tumor with exception of primary central nervous system (CNS) malignancy is permitted.
PRE-REGISTRATION: Patients older than 21 years must have a solid tumor considered by study doctor to be of the childhood cancer type.
Diagnosis during dose escalation (Part 1) - Pathologically documented, definitively diagnosed non-resectable advanced solid tumor.
Group 4 - patients must have a pathologically documented, definitively diagnosed advanced solid tumor with a RET alteration, other than NSCLC and MTC.
Patients must have pathologically confirmed diagnosis of a solid tumor cancer for which there is no known standard therapy capable of extending life expectancy
Pathologic proven diagnosis of solid tumor malignancy
Subjects with a histologic diagnosis of solid tumor cancers of epithelial origin.
Histologic or cytologic confirmation of a solid malignancy with established intolerance or refractoriness to standard therapies
Pathologic proven diagnosis of solid tumor malignancy
Part 3: advanced solid tumor or hematologic malignancy
Part 4: select advanced solid tumor or hematologic malignancy
Histologic confirmation of advanced solid tumors
Subjects with any previously treated advanced (metastatic or refractory) solid tumor
Subjects must have a previously treated advanced solid tumor to be eligible
Solid tumor contact with SMA > 180°
Subject must have advanced solid tumor that is not amenable to surgical resection or other approved therapeutic options that have demonstrated clinical benefit.
History of hematologic or primary solid tumor malignancy, unless no evidence of that disease for 5 years
Have biomarker-positive solid tumor
Advanced solid tumor for which no other higher priority therapies are available
Patient with solid tumor malignancy with leptomeningeal metastases established radiographically and/or through CSF cytology.
Patients must have radiographically-confirmed recurrent brain metastases from a solid tumor after WBRT
A solid tumor diagnosis in the setting of:
Pathologic diagnosis of solid tumor malignancy that is locally advanced or metastatic at time of Screening with documented HER2 expression.
Pathologically documented diagnosis of advanced solid tumor malignancy that progressed after appropriate prior therapy or has no potential for cure with currently available treatments.
Phase 1a: Have histologic or cytologic confirmation of advanced solid tumor
Subject must have a pathologically documented, definitively diagnosed, advanced solid tumor
Diagnosis of an advanced solid tumor malignancy.
Have histologic or cytologic documentation of solid tumor including EGFR mutated (EGFRm) NSCLC
Part A: Any type of solid tumor (\all comer\)
Relapsed or progressive advanced solid tumor malignancies
Advanced solid tumors with histologic diagnosis confirming cancer
Part 1 (enrollment closed): an advanced, incurable solid tumor
Part 2 (enrollment closed): an advanced, incurable solid tumor for whom a taxane would be considered a reasonable chemotherapy option
Advanced solid tumor malignancy
Patient has a confirmed diagnosis of a select solid tumor (except ALK+ NSCLC) or hematological malignancy and is in need of treatment because of radiologic progression or relapse.
Solid tumor cohort (B1) specific criteria
Patients with solid tumor other than CRC.
Pathologic proven diagnosis of solid tumor malignancy
Subjects must have a pathologically documented, definitively diagnosed, advanced solid tumor
Phase I: Diagnosis of recurrent, metastatic or primary unresectable solid tumor that does not have curative standard treatment
Histologic or cytologic confirmation of a solid malignancy
Has histological diagnosis of a primary solid tumor malignancy that meets study criteria
Diagnosis of a solid tumor malignancy (any stage)
Adults with a primary diagnosis of any advanced solid tumor cancer within the last 3 years
Solid tumor survivors with no evidence of disease
Solid tumor cancer diagnosis
Pathologically-confirmed solid tumor or hematologic malignancy with symptomatic bone metastases
=< 30 days post diagnosis of a solid tumor or lymphoma
Histologic diagnosis of malignancy of a solid organ or lymphoma
Incurable solid tumor malignancy
Subjects with histological diagnosis of incurable cancer (solid tumor)
Diagnosis of a metastatic or incurable solid tumor
Participants with advanced solid tumor that is not amenable to surgical resection or other approved therapeutic options.
Diagnosis of a proven solid tumors or newly diagnosed mass strongly suspected to represent a solid tumor
Patients with histopathologic diagnosis of a solid tumor. All solid tumors will be considered, but patients with breast, pancreas, and colorectal masses will be prioritized.
Patients with an extracoelomic solid tumor requiring SLN biopsy
Have an undiagnosed suspicious solid or mostly solid thyroid nodule.;
Patients with histologic or cytologic diagnosis of advanced or metastatic solid tumors or lymphomas for which no curative or life-prolonging therapies exist.
Have a confirmed diagnosis of advanced, refractory solid tumors and tumor progression or treatment intolerance to at least 1 prior therapy.
Confirmed advanced solid tumor or hematologic malignancy